Shareholding disclosure

HBM BioVentures AG

Declared position

20.11%

Threshold

Crossed upwards

Timeline

Published

17.02.2012

Transaction

08.02.2012

Voting rights breakdown

Voting rights acquired20.11%

Voting rights sold0%

Below threshold0%

Notice details

CategorySingle shareholder

ExchangeXSWX

Notification ID

TAC2F00013

Beneficial owner

HBM BioVentures AG

Declared address

HBM BioVentures AG, 6300 Zug

Bei HBM BioVentures (Cayman) Ltd handelt es sich um eine hundertprozentige Tochtergesellschaft der HBM BioVentures AG, Zug. Die gemeldete Beteiligung wird direkt von der HBM BioVentures (Cayman) Ltd gehalten.

Open shareholder profile Open company profile

Back to the feed

Shareholding disclosure

HBM BioVentures AG

Basilea Pharmaceutica AG, Allschwil17.02.2012TAC2F00013

Disclosure summary

HBM BioVentures AG disclosed a holding in Basilea Pharmaceutica AG, Allschwil on the acquisition side, published by SIX Exchange Regulation on 17.02.2012, at 20.11% of voting rights. Notice category: Single shareholder.

Disclosed position

20.11%

Voting rights acquired

Voting rights acquired20.11%

Voting rights sold0%

Below threshold0%

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open

Disclosure detail

HBM BioVentures AG disclosed a holding in Basilea Pharmaceutica AG, Allschwil, published on 17.02.2012.

Publication date17.02.2012

Transaction date08.02.2012

Issuing companyBasilea Pharmaceutica AG, Allschwil

Beneficial ownerHBM BioVentures AG

Declared addressHBM BioVentures AG, 6300 Zug

CategorySingle shareholder

Voting rights acquired20.11%

Voting rights sold0%

Below threshold0%

ExchangeXSWX

Notification IDTAC2F00013

Commercial register

CHE-101.849.760

Registered

Zefix record

Conditions

Bei HBM BioVentures (Cayman) Ltd handelt es sich um eine hundertprozentige Tochtergesellschaft der HBM BioVentures AG, Zug. Die gemeldete Beteiligung wird direkt von der HBM BioVentures (Cayman) Ltd gehalten.

Source: SIX Exchange Regulation · Publication date: 17.02.2012

These figures aggregate public disclosures. They are not investment advice.

insider24.ch

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open